Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

Healthcare
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing... see more

Recent & Breaking News (TSXV:RX)

BioSyent Releases Q2 and Six Month Results-Q2 Sales Increase 72%, Net Income After Tax Up 112%

Marketwired August 21, 2014

BioSyent Pharma (V.RX) inks exclusive licensing and distribution deal

Stockhouse Editorial July 23, 2014

BioSyent Pharma Signs Exclusive Licensing and Distribution Agreement For New Urgent Care Drug Product

Marketwired July 23, 2014

BioSyent Inc. (TSXV:RX) is the Subject of StockPotentials Report by eResearch Corp - Video Summary of Report Posted on www.investmentpitch.com

Thomson Reuters ONE July 7, 2014

eResearch Issues Stock Potentials Report on BioSyent Inc.

Accesswire July 3, 2014

BioSyent to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference

Marketwired June 13, 2014

BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies with a 5 year Revenue Growth Rate of 608%

Marketwired June 12, 2014

BioSyent Pharma Receives Health Canada Approval to Market New Urgent Care Product

Marketwired June 12, 2014

BioSyent Annual General Meeting of Shareholders - June 10, 2014

Marketwired June 6, 2014

BioSyent to Present at the 2014 Marcum MicroCap Investor Conference

Marketwired May 23, 2014

BioSyent Pharma Launches New RepaGyn® Hormone-Free Vaginal Suppositories

Marketwired May 21, 2014

BioSyent Releases First Quarter 2014 Results-Sales Increase 59%, Net Income After Tax Up 49%

Marketwired May 16, 2014

BioSyent Releases Q4 and Full Year 2013 Results: Full Year Sales Increase 55%, Net Income Up 25%, 3 Year CAGR 67%, Q4 Sales Increase 61%

Marketwired March 12, 2014

BioSyent Pharma Signs Exclusive Licence and Distribution Agreement for a New Gastrointestinal Health Product Already Approved by Health Canada-2014 Launch Planned

Marketwired March 4, 2014

BioSyent Named to the 2014 TSX Venture Top 50(R) Ranking-Only TSX Venture Company to Be Recognized as a Top Performer for the Past 3 Consecutive Years

Marketwired February 13, 2014

BioSyent Announces Appointment of New Director

Marketwired January 16, 2014

BioSyent to Present at the LD Micro VI Investor Conference

Marketwired December 2, 2013

Small cap results digest: Gobimin (V.GMN) drops, GreenStar Agricultural (V.GRE) jumps and LED Medical Diagnostics (V.LMD) stumbles

Gaalen Engen November 21, 2013

BioSyent Releases Q3 and Nine Month Results-Nine Month Sales Increase 53% and Profit Before Tax Up 77%

Marketwired November 21, 2013

BioSyent Pharma Signs Exclusive Licence and Distribution Agreement for a New Women's Health Product Already Approved by Health Canada-2014 Launch Planned

Marketwired October 1, 2013